Abbott Laboratories (ABT) Non-Current Deferred Tax Liability (2010 - 2021)

Abbott Laboratories has disclosed Non-Current Deferred Tax Liability across 12 years of filings, most recently posting $1.4 billion for Q4 2021.

• In Q4 2021, Non-Current Deferred Tax Liability fell 1.0% year-over-year to $1.4 billion; the TTM figure through Dec 2021 stood at $1.4 billion (down 1.0% YoY), while the FY2021 annual figure was $1.4 billion, down 1.0% from the prior year.
• Non-Current Deferred Tax Liability came in at $1.4 billion for Q4 2021 at Abbott Laboratories, down from $1.4 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.1 billion in Q4 2018 to a low of $1.4 billion in Q4 2021.
• Average Non-Current Deferred Tax Liability over 5 years is $1.7 billion, with a median of $1.5 billion recorded in 2019.
• Year-over-year, Non-Current Deferred Tax Liability soared 463.48% in 2017 and decreased 24.81% in 2019.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.0 billion in 2017, then increased by 2.49% to $2.1 billion in 2018, then declined by 24.81% to $1.5 billion in 2019, then decreased by 9.06% to $1.4 billion in 2020, then slipped by 1.0% to $1.4 billion in 2021.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.4 billion in Q4 2021, $1.4 billion in Q4 2020, and $1.5 billion in Q4 2019.